Literature DB >> 16179639

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease.

John R Hurst1, Wayomi R Perera, Tom M A Wilkinson, Gavin C Donaldson, Jadwiga A Wedzicha.   

Abstract

RATIONALE: In addition to pulmonary involvement, stable chronic obstructive pulmonary disease (COPD) is associated with nasal and systemic inflammation. Although exacerbations of COPD are associated with increased pulmonary and systemic inflammation, determinants of the systemic response remain obscure, and nor is it known whether there is nasal involvement.
OBJECTIVES: To investigate upper airway, lower airway, and systemic inflammation at exacerbation of COPD.
METHODS: We sampled sputum, nasal wash, and serum from 41 exacerbations (East London cohort) for analysis of pathogenic microorganisms and inflammatory indices (sputum/nasal wash leukocytes, interleukin [IL]-6, IL-8, and myeloperoxidase; serum IL-6 and C-reactive protein). Values were compared with stable COPD.
MEASUREMENTS AND MAIN RESULTS: Exacerbation of COPD is associated with greater nasal, sputum, and serum inflammation than the stable state. At exacerbation, inflammatory markers were highly correlated within nasal wash and serum (all r >/= 0.62, p < 0.001), but not sputum. The degree of upper airway inflammation correlated with the degree of lower airway inflammation (e.g., nasal wash/sputum myeloperoxidase; r = 0.50, p = 0.001). The degree of systemic inflammation correlated with the degree of lower airway inflammation (e.g., serum IL-6/sputum IL-8; r = 0.35, p = 0.026), and was greater in the presence of a sputum bacterial pathogen (29.0 g/dl C-reactive protein difference, p = 0.002). We did not find relationships between the upper airway and systemic compartments.
CONCLUSIONS: Exacerbation of COPD is associated with pan-airway inflammation; the systemic inflammatory response is proportional to that occurring in the lower airway and greater in the presence of a bacterial pathogen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179639     DOI: 10.1164/rccm.200505-704OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  93 in total

1.  What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines.

Authors:  J R Hurst; J A Wedzicha
Journal:  Thorax       Date:  2007-03       Impact factor: 9.139

2.  Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism.

Authors:  J A Wedzicha; J R Hurst
Journal:  Thorax       Date:  2007-02       Impact factor: 9.139

3.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

Review 4.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Omar A Minai; Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

5.  Neutrophil CD64 Expression as a Diagnostic Marker in Patients Hospitalized with Exacerbations of COPD: A Prospective Observational Study.

Authors:  Elena Titova; Marthe Wedø Aune; Kristin Fonn; Anne Hildur Henriksen; Arne Åsberg
Journal:  Lung       Date:  2015-07-15       Impact factor: 2.584

6.  Evaluation of IL-8 nasal lavage levels and the effects of nasal involvement on disease severity in patients with stable chronic obstructive pulmonary disease.

Authors:  Hacer Celik; Serdar Akpinar; Hayriye Karabulut; Pinar Oktar; Berna Dursun; Huyla Celenk Erguden; Sibel Gunay; Tugrul Sipit
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

7.  SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling.

Authors:  Desiree Anthony; Jonathan L McQualter; Maria Bishara; Ee X Lim; Selcuk Yatmaz; Huei Jiunn Seow; Michelle Hansen; Michelle Thompson; John A Hamilton; Louis B Irving; Bruce D Levy; Ross Vlahos; Gary P Anderson; Steven Bozinovski
Journal:  FASEB J       Date:  2014-05-20       Impact factor: 5.191

8.  Rhinosinusitis in COPD: symptoms, mucosal changes, nasal lavage cells and eicosanoids.

Authors:  Violetta M Piotrowska; Wojciech J Piotrowski; Zofia Kurmanowska; Jerzy Marczak; Paweł Górski; Adam Antczak
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

9.  Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study.

Authors:  John R Hurst; Gavin C Donaldson; Jennifer K Quint; James J P Goldring; Anant R C Patel; Jadwiga A Wedzicha
Journal:  BMC Pulm Med       Date:  2010-10-20       Impact factor: 3.317

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.